BioSpace News Archive

We are excited to announce that Technical Safety Services, Inc (TSS) has acquired AL-TAR Services, Inc (AL-TAR).

IDEXX Laboratories, Inc., a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has scheduled the release of its 2021 fourth quarter and full year financial results for Wednesday, February 2, 2022 before the market opens.

PROCEPT® BioRobotics Corporation, a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2021.

NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, announced its preliminary, unaudited revenue for the fourth quarter and full-year ended December 31, 2021.

Iridex Corporation provided preliminary unaudited operational and financial results for the fourth quarter and full year ended January 1, 2022.

Aclaris Therapeutics, Inc. provides an update on the status of certain of its clinical programs and on its research and development operations.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-301 for the treatment of signs and symptoms of Dry Eye Disease (DED).

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-302 for the treatment of presbyopia.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 41,800 shares of the Company’s common stock at an exercise price per share of $37.56, which was the closing price on January 10, 2022.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, announced certain unaudited preliminary fourth quarter and full-year 2021 revenue results.